The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / Secukinumab Meets 5-Year Benchmark for Psoriasis

Secukinumab Meets 5-Year Benchmark for Psoriasis

October 6, 2017 • By Michele B. Kaufman, PharmD, BCGP

  • Tweet
  • Email
Print-Friendly Version / Save PDF

In 2015, the U.S. Food and Drug Administration (FDA) approved secukinumab (Cosentyx), the first fully-human IL-17A inhibitor approved to treat psoriasis, psoriatic arthritis (PsA) and ankylosing spondylitis (AS).1 And data recently presented at the 26th European Academy of Dermatology and Venereology (EADV) Congress in Geneva, Switzerland, demonstrates sustained efficacy and safety. The research in patients with moderate to severe plaque psoriasis showed that secukinumab conveyed high- and long-lasting skin clearance at five years.

You Might Also Like
  • Rheumatology Drug Updates: Efficacy Studied Following Accelerated Drug Approvals; Plus Secukinumab Meets Benchmark for Psoriasis
  • Risankizumab Demonstrates Superiority to Secukinumab for Plaque Psoriasis
  • Plaque Psoriasis: Secukinumab Beats Ustekinumab in a Head-to Head Clinical Trial & Ixekizumab Helps Improve Productivity
Also By This Author
  • Pegloticase & Methotrexate Combination Therapy May Benefit Patients with Uncontrolled Gout

In the SCULPTURE study, Psoriasis Area and Severity Index (PASI) 75 responders at Week 12 were randomized to double-blind maintenance treatment of 300 or 150 mg secukinumab given at a four-week, fixed-interval regimen or as needed. Patients who completed 52 weeks of the SCULPTURE study (N=642) were eligible to continue the same dose and regimen in the extension study. The five-year extension study (A2304E1) is a multicenter, double-blind and open-label extension of the Phase 3 SCULPTURE study.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

The primary objective of the open-label extension was to assess the long-term safety and tolerability of secukinumab in patients with moderate to severe plaque psoriasis. Efficacy measures were the proportion of patients achieving PASI 75, PASI 90 and PASI 100. At Year 1, the PASI 75 response rate was 89%, and the PASI 90 response rate was 69%. This high rate maintained at Year 5, with a PASI 75 response rate of 89% and a PASI 90 response rate of 66%. Additionally at Year 1, 44% of psoriasis patients achieved completely clear skin (PASI 100), and this rate was maintained to Year 5 (41%). The drug continued to exhibit a favorable and consistent safety profile, with low immunogenicity.


Michele B. Kaufman, PharmD, BCGP, is a freelance medical writer based in New York City and a pharmacist at New York Presbyterian Lower Manhattan Hospital.

References

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE
  1. Novartis. Press release: Novartis’ Cosentyx sets new benchmark in psoriasis with robust five-year sustained Phase III efficacy and safety data. 2017 Sep 19.

Filed Under: Biologics & Biosimilars, Spondyloarthritis Tagged With: Ankylosing Spondylitis, Psoriasis, Psoriatic Arthritis, secukinumab

You Might Also Like:
  • Rheumatology Drug Updates: Efficacy Studied Following Accelerated Drug Approvals; Plus Secukinumab Meets Benchmark for Psoriasis
  • Risankizumab Demonstrates Superiority to Secukinumab for Plaque Psoriasis
  • Plaque Psoriasis: Secukinumab Beats Ustekinumab in a Head-to Head Clinical Trial & Ixekizumab Helps Improve Productivity
  • Study Finds Mirikizumab Superior to Secukinumab for Plaque Psoriasis

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Meeting Abstracts

Browse and search abstracts from the ACR Convergence and ACR/ARP Annual Meetings going back to 2012.

Visit the Abstracts site »

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)